Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.

What Is Known And Objective: Infliximab is an anti-tumour necrosis factor agent used in the treatment of inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. While the use of infliximab is well established in the treatment of IBD, there are now four recently FDA-approved infliximab biosimilars that are increasingly used due to their cost-benefit for patients, institutions and payors. In addition, shortening the length of infliximab infusions from 120 min (standard infusion) to 60 min or less (rapid infusion) has been shown to safely provide further cost-benefit while also improving patient convenience.

Fatal Aortoesophageal Fistula Complicating Placement of a 20-mm Lumen-Apposing Metal Stent for Refractory Esophagojejunal Anastomotic Stricture.

We report the case of a patient with a benign refractory esophagojejunal anastomotic stricture for which a 20-mm lumen-apposing metal stent was placed, resulting in a fatal aortoenteric fistula. We report this case to alert others to this potential complication of LAMS placement for esophageal strictures and recommend caution when using the 20-mm LAMS in similar settings.